Preview

Mass Spectroscopy

Good Essays
Open Document
Open Document
4272 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Mass Spectroscopy
ARTICLE

Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study
Fumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, Heinrich Roder, Robert Gray, Kazuo Kasahara, Makoto Nishio, Julie Brahmer, Anna Spreafico, Vienna Ludovini, Pierre P. Massion, Rafal Dziadziuszko, Joan Schiller, Julia Grigorieva, Maxim Tsypin, Stephen W. Hunsucker, Richard Caprioli, Mark W. Duncan, Fred R. Hirsch, Paul A. Bunn Jr, David P. Carbone
Downloaded from http://jnci.oxfordjournals.org/ by guest on September 13, 2012

Background

Some but not all patients with non–small-cell lung cancer (NSCLC) respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). We developed and tested the ability of a predictive algorithm based on matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) analysis of pretreatment serum to identify patients who are likely to benefit from treatment with EGFR TKIs. Serum collected from NSCLC patients before treatment with gefitinib or erlotinib were analyzed by MALDI MS. Spectra were acquired independently at two institutions. An algorithm to predict outcomes after treatment with EGFR TKIs was developed from a training set of 139 patients from three cohorts. The algorithm was then tested in two independent validation cohorts of 67 and 96 patients who were treated with gefitinib and erlotinib, respectively, and in three control cohorts of patients who were not treated with EGFR TKIs. The clinical outcomes of survival and time to progression were analyzed. An algorithm based on eight distinct m/z features was developed based on outcomes after EGFR TKI therapy in training set patients. Classifications based on spectra acquired at the two institutions had a concordance of 97.1%. For both validation cohorts, the classifier identified patients who showed improved



References: Downloaded from http://jnci.oxfordjournals.org/ by guest on September 13, 2012 Methods JNCI | Articles 841 Downloaded from http://jnci.oxfordjournals.org/ by guest on September 13, 2012 842 Articles | JNCI Downloaded from http://jnci.oxfordjournals.org/ by guest on September 13, 2012

You May Also Find These Documents Helpful

  • Powerful Essays

    Bortezomib And Irinotecan

    • 1511 Words
    • 7 Pages

    Preclinical studies reported anti-tumour response of bortezomib and Irinotecan combination and suggested that prevention of NF-kB…

    • 1511 Words
    • 7 Pages
    Powerful Essays
  • Satisfactory Essays

    Mohammed Kashani-Sabet, Javier Rangel, Sima Torabian, Mehdi Nosrati, Jeff Simko, David M. Jablons, Dan H. Moore, Chris Haqq, James R. Miller, Richard W. Sagebiel. (2009). A multi-marker assay to distinguish malignant melanomas from benign nevi. Proceedings of the National Academy of Sciences of the United States of America, Volume 106. Retrieved from http://www.pnas.org/content/106/15/6268.full.pdf…

    • 521 Words
    • 3 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Head Injuries in Football

    • 502 Words
    • 3 Pages

    Vande, Woude George F., and Georg Klein. Advances in Cancer Research. Amsterdam: Elsevier - Academic, 2007. Print.…

    • 502 Words
    • 3 Pages
    Satisfactory Essays
  • Good Essays

    Early diagnosis can also transform the design and execution of clinical trials to test new treatments.…

    • 1221 Words
    • 4 Pages
    Good Essays
  • Good Essays

    Biocon

    • 673 Words
    • 2 Pages

    The current market opportunity of BIOMAb is limited but the future is going to be bigger. In 2004, the 5-year prevalence (number of people diagnosed with cancer and still alive after 5 years) was 375,000 and the incidence (new cases per year) was 132,000 for head and neck cancer in India. However, only 1% percent of the Indian population can afford the drug. According to Biocon estimates in 2007, the market potential for BIOMAb in head and neck cancer based on incidence and % affordability was 1,900 patients new cases per year.…

    • 673 Words
    • 2 Pages
    Good Essays
  • Satisfactory Essays

    With the recent dramatic increase in research in targeted therapies has come an increase in use of biomarker endpoints in all phases. These are not generally considered to be clinical benefit endpoints by the regulatory agencies.…

    • 80 Words
    • 1 Page
    Satisfactory Essays
  • Satisfactory Essays

    Barrett, Drue H.; Resnick, Heidi S.; Foy, David W.; Dansky, Bonnie S.; Flanders, W. Dana; Stroup, Nancy E.…

    • 556 Words
    • 3 Pages
    Satisfactory Essays
  • Good Essays

    Autism

    • 732 Words
    • 3 Pages

    Epidermal growth factor receptor (EGFR) also known as HER1 or ErbB1 is a protein found on the surface of cells that is found in high levels of cancer cells. EGFR binds to this receptor protein to allow cells to grow and divide. It plays an important role in the regulation of survival, the spread of…

    • 732 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Carlo C, Rada P, McCarthy J, Patten C, Nicole M, Chadeayne A, and Hoebel, G., B.…

    • 1665 Words
    • 7 Pages
    Good Essays
  • Better Essays

    Lung Cancer

    • 1750 Words
    • 7 Pages

    Lung cancer is “the uncontrolled growth of abnormal cells in one or both lungs”. These abnormal cells do not carry out the functions of normal lung cells and do not develop into healthy lung tissue. As they grow, “the abnormal cells can form tumors and interfere with the functioning of the lung, which provides oxygen to the body via the blood”. There are two major types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Staging lung cancer is based on whether the cancer is local or has spread from the lungs to the lymph nodes or other organs. Because the lungs are large, tumors can grow in them for a long time before they are found. Even when symptoms—such as coughing and fatigue—do occur, people think they are due to other causes. For this reason, “early-stage lung cancer (stages I and II) is difficult to detect. Most people with lung cancer are diagnosed at stages III and IV. Non-small cell lung cancer accounts for about 85 percent of lung cancers”(Lung Cancer 101.). The most common form is called Adenocarcinoma.…

    • 1750 Words
    • 7 Pages
    Better Essays
  • Powerful Essays

    lung cancer

    • 713 Words
    • 3 Pages

    Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world (Humam Kadara,Mohamed Kabbout,&Ignacio Wistuba ,2011). Lung adenocarcinomas are a major subtype of non-small-cell lung cancers, are increasing in incidence globally in both males and females and in smokers and non-smokers, and are the cause for almost 50% of deaths attributable to lung cancer and the high mortality of this disease is in part due to the late diagnosis of the majority of lung cancers after regional or distant spread of the malignancy (Humam Kadara,Mohamed Kabbout,&Ignacio Wistuba 2011). Joseph E.Tota (2013) stated that by far, the most important risk factor for lung cancer is smoking data from screening trials have shown that the risk of death from lung cancer can be reduced by approximately 20% when CT screening is applied to higher-risk patients (J.G. Ravenel, Ed, 2013).…

    • 713 Words
    • 3 Pages
    Powerful Essays
  • Good Essays

    Lung cancer is one of the top 3 cancer issues in the world. The number of lung cancer patients needs to be dropped because it’s very dangerous, it’s deadly, and it is still rising in deaths today.…

    • 643 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Breast Cancer

    • 461 Words
    • 2 Pages

    Lung cancer genetic testing, is the use of lung cancer patients, "green beans" the size of a tissue sample, using next-generation sequencing technology, the 14 genes in lung cancer hotspot areas driven deep sequencing to detect gene mutations drive, and as a basis to optimize the development of individualized cancer targeted drug treatment programs, thus promoting individual treatment of lung cancer.…

    • 461 Words
    • 2 Pages
    Good Essays
  • Powerful Essays

    Lung Cancer

    • 1489 Words
    • 6 Pages

    Rosell R, Taron M, Camps C, López-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. October, 2003. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/14668933…

    • 1489 Words
    • 6 Pages
    Powerful Essays
  • Satisfactory Essays

    Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.…

    • 657 Words
    • 4 Pages
    Satisfactory Essays